| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911154 | Lung Cancer | 2014 | 8 Pages |
Abstract
The addition of cetuximab to platinum-based, first-line chemotherapy for advanced NSCLC significantly improved outcome for all efficacy endpoints with an acceptable safety profile, indicating a favorable benefit/risk ratio.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jean-Louis Pujol, Robert Pirker, Thomas J. Lynch, Charles A. Butts, Rafael Rosell, Frances A. Shepherd, Johan Vansteenkiste, Kenneth J. O'Byrne, Barbara de Blas, Jim Heighway, Anja von Heydebreck, Nick Thatcher,